1 Immuno-oncology Drugs Market Overview 1.1 Product Overview and Scope of Immuno-oncology Drugs 1.2 Immuno-oncology Drugs Segment by Type 1.2.1 Global Immuno-oncology Drugs Sales Growth Rate Comparison by Type (2021-2027) 1.2.2 Immune Checkpoint Inhibitors 1.2.3 Immune System Modulators 1.2.4 Cancer Vaccines 1.2.5 Oncolytic Virus 1.2.6 Others 1.3 Immuno-oncology Drugs Segment by Application 1.3.1 Global Immuno-oncology Drugs Sales Comparison by Application: (2021-2027) 1.3.2 Hospitals 1.3.3 Clinics 1.3.4 Ambulatory Surgical Centers 1.4 Global Immuno-oncology Drugs Market Size Estimates and Forecasts 1.4.1 Global Immuno-oncology Drugs Revenue 2016-2027 1.4.2 Global Immuno-oncology Drugs Sales 2016-2027 1.4.3 Immuno-oncology Drugs Market Size by Region: 2016 Versus 2021 Versus 2027 2 Immuno-oncology Drugs Market Competition by Manufacturers 2.1 Global Immuno-oncology Drugs Sales Market Share by Manufacturers (2016-2021) 2.2 Global Immuno-oncology Drugs Revenue Market Share by Manufacturers (2016-2021) 2.3 Global Immuno-oncology Drugs Average Price by Manufacturers (2016-2021) 2.4 Manufacturers Immuno-oncology Drugs Manufacturing Sites, Area Served, Product Type 2.5 Immuno-oncology Drugs Market Competitive Situation and Trends 2.5.1 Immuno-oncology Drugs Market Concentration Rate 2.5.2 The Global Top 5 and Top 10 Largest Immuno-oncology Drugs Players Market Share by Revenue 2.5.3 Global Immuno-oncology Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 2.6 Manufacturers Mergers & Acquisitions, Expansion Plans 3 Immuno-oncology Drugs Retrospective Market Scenario by Region 3.1 Global Immuno-oncology Drugs Retrospective Market Scenario in Sales by Region: 2016-2021 3.2 Global Immuno-oncology Drugs Retrospective Market Scenario in Revenue by Region: 2016-2021 3.3 North America Immuno-oncology Drugs Market Facts & Figures by Country 3.3.1 North America Immuno-oncology Drugs Sales by Country 3.3.2 North America Immuno-oncology Drugs Revenue by Country 3.3.3 U.S. 3.3.4 Canada 3.4 Europe Immuno-oncology Drugs Market Facts & Figures by Country 3.4.1 Europe Immuno-oncology Drugs Sales by Country 3.4.2 Europe Immuno-oncology Drugs Revenue by Country 3.4.3 Germany 3.4.4 France 3.4.5 U.K. 3.4.6 Italy 3.4.7 Russia 3.5 Asia Pacific Immuno-oncology Drugs Market Facts & Figures by Region 3.5.1 Asia Pacific Immuno-oncology Drugs Sales by Region 3.5.2 Asia Pacific Immuno-oncology Drugs Revenue by Region 3.5.3 China 3.5.4 Japan 3.5.5 South Korea 3.5.6 India 3.5.7 Australia 3.5.8 Taiwan 3.5.9 Indonesia 3.5.10 Thailand 3.5.11 Malaysia 3.5.12 Philippines 3.5.13 Vietnam 3.6 Latin America Immuno-oncology Drugs Market Facts & Figures by Country 3.6.1 Latin America Immuno-oncology Drugs Sales by Country 3.6.2 Latin America Immuno-oncology Drugs Revenue by Country 3.6.3 Mexico 3.6.4 Brazil 3.6.5 Argentina 3.7 Middle East and Africa Immuno-oncology Drugs Market Facts & Figures by Country 3.7.1 Middle East and Africa Immuno-oncology Drugs Sales by Country 3.7.2 Middle East and Africa Immuno-oncology Drugs Revenue by Country 3.7.3 Turkey 3.7.4 Saudi Arabia 3.7.5 U.A.E 4 Global Immuno-oncology Drugs Historic Market Analysis by Type 4.1 Global Immuno-oncology Drugs Sales Market Share by Type (2016-2021) 4.2 Global Immuno-oncology Drugs Revenue Market Share by Type (2016-2021) 4.3 Global Immuno-oncology Drugs Price by Type (2016-2021) 5 Global Immuno-oncology Drugs Historic Market Analysis by Application 5.1 Global Immuno-oncology Drugs Sales Market Share by Application (2016-2021) 5.2 Global Immuno-oncology Drugs Revenue Market Share by Application (2016-2021) 5.3 Global Immuno-oncology Drugs Price by Application (2016-2021) 6 Key Companies Profiled 6.1 Amgen, Inc 6.1.1 Amgen, Inc Corporation Information 6.1.2 Amgen, Inc Description and Business Overview 6.1.3 Amgen, Inc Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.1.4 Amgen, Inc Immuno-oncology Drugs Product Portfolio 6.1.5 Amgen, Inc Recent Developments/Updates 6.2 AstraZeneca, Plc 6.2.1 AstraZeneca, Plc Corporation Information 6.2.2 AstraZeneca, Plc Description and Business Overview 6.2.3 AstraZeneca, Plc Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.2.4 AstraZeneca, Plc Immuno-oncology Drugs Product Portfolio 6.2.5 AstraZeneca, Plc Recent Developments/Updates 6.3 Bristol-Myers Squibb 6.3.1 Bristol-Myers Squibb Corporation Information 6.3.2 Bristol-Myers Squibb Description and Business Overview 6.3.3 Bristol-Myers Squibb Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.3.4 Bristol-Myers Squibb Immuno-oncology Drugs Product Portfolio 6.3.5 Bristol-Myers Squibb Recent Developments/Updates 6.4 Celgene Corporation 6.4.1 Celgene Corporation Corporation Information 6.4.2 Celgene Corporation Description and Business Overview 6.4.3 Celgene Corporation Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.4.4 Celgene Corporation Immuno-oncology Drugs Product Portfolio 6.4.5 Celgene Corporation Recent Developments/Updates 6.5 Eli Lilly and Company 6.5.1 Eli Lilly and Company Corporation Information 6.5.2 Eli Lilly and Company Description and Business Overview 6.5.3 Eli Lilly and Company Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.5.4 Eli Lilly and Company Immuno-oncology Drugs Product Portfolio 6.5.5 Eli Lilly and Company Recent Developments/Updates 6.6 Merck & Co. 6.6.1 Merck & Co. Corporation Information 6.6.2 Merck & Co. Description and Business Overview 6.6.3 Merck & Co. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.6.4 Merck & Co. Immuno-oncology Drugs Product Portfolio 6.6.5 Merck & Co. Recent Developments/Updates 6.7 Hoffmann-La Roche AG 6.6.1 Hoffmann-La Roche AG Corporation Information 6.6.2 Hoffmann-La Roche AG Description and Business Overview 6.6.3 Hoffmann-La Roche AG Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.4.4 Hoffmann-La Roche AG Immuno-oncology Drugs Product Portfolio 6.7.5 Hoffmann-La Roche AG Recent Developments/Updates 6.8 Johnson & Johnson 6.8.1 Johnson & Johnson Corporation Information 6.8.2 Johnson & Johnson Description and Business Overview 6.8.3 Johnson & Johnson Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.8.4 Johnson & Johnson Immuno-oncology Drugs Product Portfolio 6.8.5 Johnson & Johnson Recent Developments/Updates 6.9 Novartis International AG 6.9.1 Novartis International AG Corporation Information 6.9.2 Novartis International AG Description and Business Overview 6.9.3 Novartis International AG Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.9.4 Novartis International AG Immuno-oncology Drugs Product Portfolio 6.9.5 Novartis International AG Recent Developments/Updates 6.10 AbbVie, Inc. 6.10.1 AbbVie, Inc. Corporation Information 6.10.2 AbbVie, Inc. Description and Business Overview 6.10.3 AbbVie, Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.10.4 AbbVie, Inc. Immuno-oncology Drugs Product Portfolio 6.10.5 AbbVie, Inc. Recent Developments/Updates 6.11 Pfizer Inc. 6.11.1 Pfizer Inc. Corporation Information 6.11.2 Pfizer Inc. Immuno-oncology Drugs Description and Business Overview 6.11.3 Pfizer Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.11.4 Pfizer Inc. Immuno-oncology Drugs Product Portfolio 6.11.5 Pfizer Inc. Recent Developments/Updates 6.12 Sanofi S.A. 6.12.1 Sanofi S.A. Corporation Information 6.12.2 Sanofi S.A. Immuno-oncology Drugs Description and Business Overview 6.12.3 Sanofi S.A. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.12.4 Sanofi S.A. Immuno-oncology Drugs Product Portfolio 6.12.5 Sanofi S.A. Recent Developments/Updates 6.13 EMD Serono, Inc. 6.13.1 EMD Serono, Inc. Corporation Information 6.13.2 EMD Serono, Inc. Immuno-oncology Drugs Description and Business Overview 6.13.3 EMD Serono, Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.13.4 EMD Serono, Inc. Immuno-oncology Drugs Product Portfolio 6.13.5 EMD Serono, Inc. Recent Developments/Updates 6.14 Gilead Sciences Inc. 6.14.1 Gilead Sciences Inc. Corporation Information 6.14.2 Gilead Sciences Inc. Immuno-oncology Drugs Description and Business Overview 6.14.3 Gilead Sciences Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.14.4 Gilead Sciences Inc. Immuno-oncology Drugs Product Portfolio 6.14.5 Gilead Sciences Inc. Recent Developments/Updates 6.15 Prometheus Therapeutics & Diagnostics 6.15.1 Prometheus Therapeutics & Diagnostics Corporation Information 6.15.2 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Description and Business Overview 6.15.3 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.15.4 Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product Portfolio 6.15.5 Prometheus Therapeutics & Diagnostics Recent Developments/Updates 6.16 Aduro BioTech 6.16.1 Aduro BioTech Corporation Information 6.16.2 Aduro BioTech Immuno-oncology Drugs Description and Business Overview 6.16.3 Aduro BioTech Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.16.4 Aduro BioTech Immuno-oncology Drugs Product Portfolio 6.16.5 Aduro BioTech Recent Developments/Updates 6.17 Galena Biopharma 6.17.1 Galena Biopharma Corporation Information 6.17.2 Galena Biopharma Immuno-oncology Drugs Description and Business Overview 6.17.3 Galena Biopharma Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.17.4 Galena Biopharma Immuno-oncology Drugs Product Portfolio 6.17.5 Galena Biopharma Recent Developments/Updates 6.18 Bavarian Nordic 6.18.1 Bavarian Nordic Corporation Information 6.18.2 Bavarian Nordic Immuno-oncology Drugs Description and Business Overview 6.18.3 Bavarian Nordic Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.18.4 Bavarian Nordic Immuno-oncology Drugs Product Portfolio 6.18.5 Bavarian Nordic Recent Developments/Updates 6.19 Celldex Therapeutics 6.19.1 Celldex Therapeutics Corporation Information 6.19.2 Celldex Therapeutics Immuno-oncology Drugs Description and Business Overview 6.19.3 Celldex Therapeutics Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.19.4 Celldex Therapeutics Immuno-oncology Drugs Product Portfolio 6.19.5 Celldex Therapeutics Recent Developments/Updates 6.20 ImmunoCellular Therapeutics 6.20.1 ImmunoCellular Therapeutics Corporation Information 6.20.2 ImmunoCellular Therapeutics Immuno-oncology Drugs Description and Business Overview 6.20.3 ImmunoCellular Therapeutics Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.20.4 ImmunoCellular Therapeutics Immuno-oncology Drugs Product Portfolio 6.20.5 ImmunoCellular Therapeutics Recent Developments/Updates 6.21 Incyte 6.21.1 Incyte Corporation Information 6.21.2 Incyte Immuno-oncology Drugs Description and Business Overview 6.21.3 Incyte Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.21.4 Incyte Immuno-oncology Drugs Product Portfolio 6.21.5 Incyte Recent Developments/Updates 6.22 Dendreon Corporation 6.22.1 Dendreon Corporation Corporation Information 6.22.2 Dendreon Corporation Immuno-oncology Drugs Description and Business Overview 6.22.3 Dendreon Corporation Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.22.4 Dendreon Corporation Immuno-oncology Drugs Product Portfolio 6.22.5 Dendreon Corporation Recent Developments/Updates 6.23 Agilent Technologies Inc. 6.23.1 Agilent Technologies Inc. Corporation Information 6.23.2 Agilent Technologies Inc. Immuno-oncology Drugs Description and Business Overview 6.23.3 Agilent Technologies Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.23.4 Agilent Technologies Inc. Immuno-oncology Drugs Product Portfolio 6.23.5 Agilent Technologies Inc. Recent Developments/Updates 6.24 Agenus Inc. 6.24.1 Agenus Inc. Corporation Information 6.24.2 Agenus Inc. Immuno-oncology Drugs Description and Business Overview 6.24.3 Agenus Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.24.4 Agenus Inc. Immuno-oncology Drugs Product Portfolio 6.24.5 Agenus Inc. Recent Developments/Updates 6.25 Enzo Biochem, Inc. 6.25.1 Enzo Biochem, Inc. Corporation Information 6.25.2 Enzo Biochem, Inc. Immuno-oncology Drugs Description and Business Overview 6.25.3 Enzo Biochem, Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.25.4 Enzo Biochem, Inc. Immuno-oncology Drugs Product Portfolio 6.25.5 Enzo Biochem, Inc. Recent Developments/Updates 6.26 Lonza Group 6.26.1 Lonza Group Corporation Information 6.26.2 Lonza Group Immuno-oncology Drugs Description and Business Overview 6.26.3 Lonza Group Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.26.4 Lonza Group Immuno-oncology Drugs Product Portfolio 6.26.5 Lonza Group Recent Developments/Updates 6.27 Bio-Rad Laboratories, Inc. 6.27.1 Bio-Rad Laboratories, Inc. Corporation Information 6.27.2 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Description and Business Overview 6.27.3 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.27.4 Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Product Portfolio 6.27.5 Bio-Rad Laboratories, Inc. Recent Developments/Updates 6.28 Avantor, Inc. 6.28.1 Avantor, Inc. Corporation Information 6.28.2 Avantor, Inc. Immuno-oncology Drugs Description and Business Overview 6.28.3 Avantor, Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.28.4 Avantor, Inc. Immuno-oncology Drugs Product Portfolio 6.28.5 Avantor, Inc. Recent Developments/Updates 6.29 Spring Bank Pharmaceuticals, Inc. 6.29.1 Spring Bank Pharmaceuticals, Inc. Corporation Information 6.29.2 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Description and Business Overview 6.29.3 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.29.4 Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Product Portfolio 6.29.5 Spring Bank Pharmaceuticals, Inc. Recent Developments/Updates 6.30 Ferring Pharmaceuticals 6.30.1 Ferring Pharmaceuticals Corporation Information 6.30.2 Ferring Pharmaceuticals Immuno-oncology Drugs Description and Business Overview 6.30.3 Ferring Pharmaceuticals Immuno-oncology Drugs Sales, Revenue and Gross Margin (2016-2021) 6.30.4 Ferring Pharmaceuticals Immuno-oncology Drugs Product Portfolio 6.30.5 Ferring Pharmaceuticals Recent Developments/Updates 7 Immuno-oncology Drugs Manufacturing Cost Analysis 7.1 Immuno-oncology Drugs Key Raw Materials Analysis 7.1.1 Key Raw Materials 7.1.2 Key Suppliers of Raw Materials 7.2 Proportion of Manufacturing Cost Structure 7.3 Manufacturing Process Analysis of Immuno-oncology Drugs 7.4 Immuno-oncology Drugs Industrial Chain Analysis 8 Marketing Channel, Distributors and Customers 8.1 Marketing Channel 8.2 Immuno-oncology Drugs Distributors List 8.3 Immuno-oncology Drugs Customers 9 Immuno-oncology Drugs Market Dynamics 9.1 Immuno-oncology Drugs Industry Trends 9.2 Immuno-oncology Drugs Growth Drivers 9.3 Immuno-oncology Drugs Market Challenges 9.4 Immuno-oncology Drugs Market Restraints 10 Global Market Forecast 10.1 Immuno-oncology Drugs Market Estimates and Projections by Type 10.1.1 Global Forecasted Sales of Immuno-oncology Drugs by Type (2022-2027) 10.1.2 Global Forecasted Revenue of Immuno-oncology Drugs by Type (2022-2027) 10.2 Immuno-oncology Drugs Market Estimates and Projections by Application 10.2.1 Global Forecasted Sales of Immuno-oncology Drugs by Application (2022-2027) 10.2.2 Global Forecasted Revenue of Immuno-oncology Drugs by Application (2022-2027) 10.3 Immuno-oncology Drugs Market Estimates and Projections by Region 10.3.1 Global Forecasted Sales of Immuno-oncology Drugs by Region (2022-2027) 10.3.2 Global Forecasted Revenue of Immuno-oncology Drugs by Region (2022-2027) 11 Research Finding and Conclusion 12 Methodology and Data Source 12.1 Methodology/Research Approach 12.1.1 Research Programs/Design 12.1.2 Market Size Estimation 12.1.3 Market Breakdown and Data Triangulation 12.2 Data Source 12.2.1 Secondary Sources 12.2.2 Primary Sources 12.3 Author List 12.4 Disclaimer

List of Tables Table 1. Global Immuno-oncology Drugs Sales (K Units) Growth Rate Comparison by Type (2021-2027) Table 2. Global Immuno-oncology Drugs Sales (K Units) Comparison by Application (2021-2027) Table 3. Global Immuno-oncology Drugs Market Size by Region (US$ Million) (2016 VS 2021 VS 2027) Table 4. Key Manufacturers Immuno-oncology Drugs Covered in This Study Table 5. Global Immuno-oncology Drugs Sales (K Units) of Key Manufacturers (2016-2021) Table 6. Global Immuno-oncology Drugs Sales Market Share by Manufacturers (2016-2021) Table 7. Global Immuno-oncology Drugs Revenue (US$ Million) by Manufacturers (2016-2021) Table 8. Global Immuno-oncology Drugs Revenue Share by Manufacturers (2016-2021) Table 9. Global Market Immuno-oncology Drugs Average Price (USD/Unit) of Key Manufacturers (2016-2021) Table 10. Manufacturers Immuno-oncology Drugs Manufacturing Sites and Area Served Table 11. Manufacturers Immuno-oncology Drugs Product Type Table 12. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 13. Global Immuno-oncology Drugs by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Immuno-oncology Drugs as of 2020) Table 14. Manufacturers Mergers & Acquisitions, Expansion Plans Table 15. Global Immuno-oncology Drugs Sales by Region (2016-2021) & (K Units) Table 16. Global Immuno-oncology Drugs Sales Market Share by Region (2016-2021) Table 17. Global Immuno-oncology Drugs Revenue by Region (2016-2021) & (US$ Million) Table 18. North America Immuno-oncology Drugs Sales by Country (2016-2021) & (K Units) Table 19. North America Immuno-oncology Drugs Sales Market Share by Country (2016-2021) Table 20. North America Immuno-oncology Drugs Revenue by Country (2016-2021) & (US$ Million) Table 21. North America Immuno-oncology Drugs Revenue Market Share by Country (2016-2021) Table 22. Europe Immuno-oncology Drugs Sales by Country (2016-2021) & (K Units) Table 23. Europe Immuno-oncology Drugs Sales Market Share by Country (2016-2021) Table 24. Europe Immuno-oncology Drugs Revenue by Country (2016-2021) & (US$ Million) Table 25. Europe Immuno-oncology Drugs Revenue Market Share by Country (2016-2021) Table 26. Asia Pacific Immuno-oncology Drugs Sales by Region (2016-2021) & (K Units) Table 27. Asia Pacific Immuno-oncology Drugs Sales Market Share by Region (2016-2021) Table 28. Asia Pacific Immuno-oncology Drugs Revenue by Region (2016-2021) & (US$ Million) Table 29. Asia Pacific Immuno-oncology Drugs Revenue Market Share by Region (2016-2021) Table 30. Latin America Immuno-oncology Drugs Sales by Country (2016-2021) & (K Units) Table 31. Latin America Immuno-oncology Drugs Sales Market Share by Country (2016-2021) Table 32. Latin America Immuno-oncology Drugs Revenue by Country (2016-2021) & (US$ Million) Table 33. Latin America Immuno-oncology Drugs Revenue Market Share by Country (2016-2021) Table 34. Middle East and Africa Immuno-oncology Drugs Sales by Country (2016-2021) & (K Units) Table 35. Middle East and Africa Immuno-oncology Drugs Sales Market Share by Country (2016-2021) Table 36. Middle East and Africa Immuno-oncology Drugs Revenue by Country (2016-2021) & (US$ Million) Table 37. Middle East and Africa Immuno-oncology Drugs Revenue Market Share by Country (2016-2021) Table 38. Global Immuno-oncology Drugs Sales (K Units) by Type (2016-2021) Table 39. Global Immuno-oncology Drugs Sales Market Share by Type (2016-2021) Table 40. Global Immuno-oncology Drugs Revenue (Million US$) by Type (2016-2021) Table 41. Global Immuno-oncology Drugs Revenue Share by Type (2016-2021) Table 42. Global Immuno-oncology Drugs Price (USD/Unit) by Type (2016-2021) Table 43. Global Immuno-oncology Drugs Sales (K Units) by Application (2016-2021) Table 44. Global Immuno-oncology Drugs Sales Market Share by Application (2016-2021) Table 45. Global Immuno-oncology Drugs Revenue (Million US$) by Application (2016-2021) Table 46. Global Immuno-oncology Drugs Revenue Share by Application (2016-2021) Table 47. Global Immuno-oncology Drugs Price (USD/Unit) by Application (2016-2021) Table 48. Amgen, Inc Corporation Information Table 49. Amgen, Inc Description and Business Overview Table 50. Amgen, Inc Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 51. Amgen, Inc Immuno-oncology Drugs Product Table 52. Amgen, Inc Recent Developments/Updates Table 53. AstraZeneca, Plc Corporation Information Table 54. AstraZeneca, Plc Description and Business Overview Table 55. AstraZeneca, Plc Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 56. AstraZeneca, Plc Immuno-oncology Drugs Product Table 57. AstraZeneca, Plc Recent Developments/Updates Table 58. Bristol-Myers Squibb Corporation Information Table 59. Bristol-Myers Squibb Description and Business Overview Table 60. Bristol-Myers Squibb Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 61. Bristol-Myers Squibb Immuno-oncology Drugs Product Table 62. Bristol-Myers Squibb Recent Developments/Updates Table 63. Celgene Corporation Corporation Information Table 64. Celgene Corporation Description and Business Overview Table 65. Celgene Corporation Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 66. Celgene Corporation Immuno-oncology Drugs Product Table 67. Celgene Corporation Recent Developments/Updates Table 68. Eli Lilly and Company Corporation Information Table 69. Eli Lilly and Company Description and Business Overview Table 70. Eli Lilly and Company Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 71. Eli Lilly and Company Immuno-oncology Drugs Product Table 72. Eli Lilly and Company Recent Developments/Updates Table 73. Merck & Co. Corporation Information Table 74. Merck & Co. Description and Business Overview Table 75. Merck & Co. Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 76. Merck & Co. Immuno-oncology Drugs Product Table 77. Merck & Co. Recent Developments/Updates Table 78. Hoffmann-La Roche AG Corporation Information Table 79. Hoffmann-La Roche AG Description and Business Overview Table 80. Hoffmann-La Roche AG Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 81. Hoffmann-La Roche AG Immuno-oncology Drugs Product Table 82. Hoffmann-La Roche AG Recent Developments/Updates Table 83. Johnson & Johnson Corporation Information Table 84. Johnson & Johnson Description and Business Overview Table 85. Johnson & Johnson Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 86. Johnson & Johnson Immuno-oncology Drugs Product Table 87. Johnson & Johnson Recent Developments/Updates Table 88. Novartis International AG Corporation Information Table 89. Novartis International AG Description and Business Overview Table 90. Novartis International AG Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 91. Novartis International AG Immuno-oncology Drugs Product Table 92. Novartis International AG Recent Developments/Updates Table 93. AbbVie, Inc. Corporation Information Table 94. AbbVie, Inc. Description and Business Overview Table 95. AbbVie, Inc. Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 96. AbbVie, Inc. Immuno-oncology Drugs Product Table 97. AbbVie, Inc. Recent Developments/Updates Table 98. Pfizer Inc. Corporation Information Table 99. Pfizer Inc. Description and Business Overview Table 100. Pfizer Inc. Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 101. Pfizer Inc. Immuno-oncology Drugs Product Table 102. Pfizer Inc. Recent Developments/Updates Table 103. Sanofi S.A. Corporation Information Table 104. Sanofi S.A. Description and Business Overview Table 105. Sanofi S.A. Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 106. Sanofi S.A. Immuno-oncology Drugs Product Table 107. Sanofi S.A. Recent Developments/Updates Table 108. EMD Serono, Inc. Corporation Information Table 109. EMD Serono, Inc. Description and Business Overview Table 110. EMD Serono, Inc. Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 111. EMD Serono, Inc. Immuno-oncology Drugs Product Table 112. EMD Serono, Inc. Recent Developments/Updates Table 113. Gilead Sciences Inc. Corporation Information Table 114. Gilead Sciences Inc. Description and Business Overview Table 115. Gilead Sciences Inc. Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 116. Gilead Sciences Inc. Immuno-oncology Drugs Product Table 117. Gilead Sciences Inc. Recent Developments/Updates Table 118. Prometheus Therapeutics & Diagnostics Corporation Information Table 119. Prometheus Therapeutics & Diagnostics Description and Business Overview Table 120. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 121. Prometheus Therapeutics & Diagnostics Immuno-oncology Drugs Product Table 122. Prometheus Therapeutics & Diagnostics Recent Developments/Updates Table 123. Aduro BioTech Corporation Information Table 124. Aduro BioTech Description and Business Overview Table 125. Aduro BioTech Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 126. Aduro BioTech Immuno-oncology Drugs Product Table 127. Aduro BioTech Recent Developments/Updates Table 128. Galena Biopharma Corporation Information Table 129. Galena Biopharma Description and Business Overview Table 130. Galena Biopharma Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 131. Galena Biopharma Immuno-oncology Drugs Product Table 132. Galena Biopharma Recent Developments/Updates Table 133. Bavarian Nordic Corporation Information Table 134. Bavarian Nordic Description and Business Overview Table 135. Bavarian Nordic Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 136. Bavarian Nordic Immuno-oncology Drugs Product Table 137. Bavarian Nordic Recent Developments/Updates Table 138. Celldex Therapeutics Corporation Information Table 139. Celldex Therapeutics Description and Business Overview Table 140. Celldex Therapeutics Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 141. Celldex Therapeutics Immuno-oncology Drugs Product Table 142. Celldex Therapeutics Recent Developments/Updates Table 143. ImmunoCellular Therapeutics Corporation Information Table 144. ImmunoCellular Therapeutics Description and Business Overview Table 145. ImmunoCellular Therapeutics Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 146. ImmunoCellular Therapeutics Immuno-oncology Drugs Product Table 147. ImmunoCellular Therapeutics Recent Developments/Updates Table 148. Incyte Corporation Information Table 149. Incyte Description and Business Overview Table 150. Incyte Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 151. Incyte Immuno-oncology Drugs Product Table 152. Incyte Recent Developments/Updates Table 153. Dendreon Corporation Corporation Information Table 154. Dendreon Corporation Description and Business Overview Table 155. Dendreon Corporation Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 156. Dendreon Corporation Immuno-oncology Drugs Product Table 157. Dendreon Corporation Recent Developments/Updates Table 158. Agilent Technologies Inc. Corporation Information Table 159. Agilent Technologies Inc. Description and Business Overview Table 160. Agilent Technologies Inc. Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 161. Agilent Technologies Inc. Immuno-oncology Drugs Product Table 162. Agilent Technologies Inc. Recent Developments/Updates Table 163. Agenus Inc. Corporation Information Table 164. Agenus Inc. Description and Business Overview Table 165. Agenus Inc. Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 166. Agenus Inc. Immuno-oncology Drugs Product Table 167. Agenus Inc. Recent Developments/Updates Table 168. Enzo Biochem, Inc. Corporation Information Table 169. Enzo Biochem, Inc. Description and Business Overview Table 170. Enzo Biochem, Inc. Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 171. Enzo Biochem, Inc. Immuno-oncology Drugs Product Table 172. Enzo Biochem, Inc. Recent Developments/Updates Table 173. Lonza Group Corporation Information Table 174. Lonza Group Description and Business Overview Table 175. Lonza Group Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 176. Lonza Group Immuno-oncology Drugs Product Table 177. Lonza Group Recent Developments/Updates Table 178. Bio-Rad Laboratories, Inc. Corporation Information Table 179. Bio-Rad Laboratories, Inc. Description and Business Overview Table 180. Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 181. Bio-Rad Laboratories, Inc. Immuno-oncology Drugs Product Table 182. Bio-Rad Laboratories, Inc. Recent Developments/Updates Table 183. Avantor, Inc. Corporation Information Table 184. Avantor, Inc. Description and Business Overview Table 185. Avantor, Inc. Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 186. Avantor, Inc. Immuno-oncology Drugs Product Table 187. Avantor, Inc. Recent Developments/Updates Table 188. Spring Bank Pharmaceuticals, Inc. Corporation Information Table 189. Spring Bank Pharmaceuticals, Inc. Description and Business Overview Table 190. Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 191. Spring Bank Pharmaceuticals, Inc. Immuno-oncology Drugs Product Table 192. Spring Bank Pharmaceuticals, Inc. Recent Developments/Updates Table 193. Ferring Pharmaceuticals Corporation Information Table 194. Ferring Pharmaceuticals Description and Business Overview Table 195. Ferring Pharmaceuticals Immuno-oncology Drugs Sales (K Units), Revenue (Million US$), Price (USD/Unit) and Gross Margin (2016-2021) Table 196. Ferring Pharmaceuticals Immuno-oncology Drugs Product Table 197. Ferring Pharmaceuticals Recent Developments/Updates Table 198. Production Base and Market Concentration Rate of Raw Material Table 199. Key Suppliers of Raw Materials Table 200. Immuno-oncology Drugs Distributors List Table 201. Immuno-oncology Drugs Customers List Table 202. Immuno-oncology Drugs Market Trends Table 203. Immuno-oncology Drugs Growth Drivers Table 204. Immuno-oncology Drugs Market Challenges Table 205. Immuno-oncology Drugs Market Restraints Table 206. Global Immuno-oncology Drugs Sales Forecast by Type (2022-2027) & (K Units) Table 207. Global Immuno-oncology Drugs Sales Market Share Forecast by Type (2022-2027) Table 208. Global Immuno-oncology Drugs Revenue Forecast by Type (2022-2027) & (US$ Million) Table 209. Global Immuno-oncology Drugs Revenue Market Share Forecast by Type (2022-2027) Table 210. Global Immuno-oncology Drugs Sales Forecast by Application (2022-2027) & (K Units) Table 211. Global Immuno-oncology Drugs Sales Market Share Forecast by Application (2022-2027) Table 212. Global Immuno-oncology Drugs Revenue Forecast by Application (2022-2027) & (US$ Million) Table 213. Global Immuno-oncology Drugs Revenue Market Share Forecast by Application (2022-2027) Table 214. Global Immuno-oncology Drugs Sales Forecast by Region (2022-2027) & (K Units) Table 215. Global Immuno-oncology Drugs Sales Market Share Forecast by Region (2022-2027) Table 216. Global Immuno-oncology Drugs Revenue Forecast by Region (2022-2027) & (US$ Million) Table 217. Global Immuno-oncology Drugs Revenue Market Share Forecast by Region (2022-2027) Table 218. Research Programs/Design for This Report Table 219. Key Data Information from Secondary Sources Table 220. Key Data Information from Primary Sources List of Figures Figure 1. Product Picture of Immuno-oncology Drugs Figure 2. Global Immuno-oncology Drugs Market Share by Type in 2020 & 2027 Figure 3. Immune Checkpoint Inhibitors Product Picture Figure 4. Immune System Modulators Product Picture Figure 5. Cancer Vaccines Product Picture Figure 6. Oncolytic Virus Product Picture Figure 7. Others Product Picture Figure 8. Global Immuno-oncology Drugs Market Share by Application in 2020 & 2027 Figure 9. Hospitals Figure 10. Clinics Figure 11. Ambulatory Surgical Centers Figure 12. Global Immuno-oncology Drugs Revenue, (US$ Million), 2016 VS 2021 VS 2027 Figure 13. Global Immuno-oncology Drugs Market Size 2016-2027 (US$ Million) Figure 14. Global Immuno-oncology Drugs Sales 2016-2027 (K Units) Figure 15. Global Immuno-oncology Drugs Market Size Market Share by Region: 2016 VS 20210 VS 2027 Figure 16. Immuno-oncology Drugs Sales Share by Manufacturers in 2020 Figure 17. Global Immuno-oncology Drugs Revenue Share by Manufacturers in 2020 Figure 18. The Global 5 and 10 Largest Immuno-oncology Drugs Players: Market Share by Revenue in 2020 Figure 19. Immuno-oncology Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2021 Figure 20. Global Immuno-oncology Drugs Sales Market Share by Region (2016-2021) Figure 21. Global Immuno-oncology Drugs Sales Market Share by Region in 2020 Figure 22. Global Immuno-oncology Drugs Revenue Market Share by Region (2016-2021) Figure 23. Global Immuno-oncology Drugs Revenue Market Share by Region in 2020 Figure 24. U.S. Immuno-oncology Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 25. Canada Immuno-oncology Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 26. Germany Immuno-oncology Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 27. France Immuno-oncology Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 28. U.K. Immuno-oncology Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 29. Italy Immuno-oncology Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 30. Russia Immuno-oncology Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 31. China Immuno-oncology Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 32. Japan Immuno-oncology Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 33. South Korea Immuno-oncology Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 34. India Immuno-oncology Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 35. Australia Immuno-oncology Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 36. Taiwan Immuno-oncology Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 37. Indonesia Immuno-oncology Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 38. Thailand Immuno-oncology Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 39. Malaysia Immuno-oncology Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 40. Philippines Immuno-oncology Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 41. Vietnam Immuno-oncology Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 42. Mexico Immuno-oncology Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 43. Brazil Immuno-oncology Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 44. Argentina Immuno-oncology Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 45. Turkey Immuno-oncology Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 46. Saudi Arabia Immuno-oncology Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 47. U.A.E Immuno-oncology Drugs Revenue Growth Rate (2016-2021) (US$ Million) Figure 48. Sales Market Share of Immuno-oncology Drugs by Type (2016-2021) Figure 49. Sales Market Share of Immuno-oncology Drugs by Application (2016-2021) Figure 50. Sales Market Share of Immuno-oncology Drugs by Application in 2020 Figure 51. Revenue Share of Immuno-oncology Drugs by Application (2016-2021) Figure 52. Revenue Share of Immuno-oncology Drugs by Application in 2020 Figure 53. Manufacturing Cost Structure of Immuno-oncology Drugs Figure 54. Manufacturing Process Analysis of Immuno-oncology Drugs Figure 55. Immuno-oncology Drugs Industrial Chain Analysis Figure 56. Channels of Distribution Figure 57. Distributors Profiles Figure 58. Bottom-up and Top-down Approaches for This Report Figure 59. Data Triangulation Figure 60. Key Executives Interviewed

Amgen, Inc AstraZeneca, Plc Bristol-Myers Squibb Celgene Corporation Eli Lilly and Company Merck & Co. Hoffmann-La Roche AG Johnson & Johnson Novartis International AG AbbVie, Inc. Pfizer Inc. Sanofi S.A. EMD Serono, Inc. Gilead Sciences Inc. Prometheus Therapeutics & Diagnostics Aduro BioTech Galena Biopharma Bavarian Nordic Celldex Therapeutics ImmunoCellular Therapeutics Incyte Dendreon Corporation Agilent Technologies Inc. Agenus Inc. Enzo Biochem, Inc. Lonza Group Bio-Rad Laboratories, Inc. Avantor, Inc. Spring Bank Pharmaceuticals, Inc. Ferring Pharmaceuticals